Slide 1: Exchange cover letter for investor presentation
July 28, 2026 To, The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Mumbai 400 001. Bandra (East), Mumbai 400 051. Symbol: RPG
Slide 2: Q1 FY27 Performance - Investors' Presentation
Q1 FY27 Performance RPG Life Sciences Investors’ Presentation July 2026 1
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: Powered by Passion, Driven by Ethics
RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Domestic Formulations (DF) Leader in Immunosuppr
Slide 6: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies
RPG Life Sciences: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Textbook Brands Specialty Chronic Life Cycle Management (Existing Products) Rheumatology Trastuzumab Azathio
Slide 7: Business Operations
Business Operations 6
Slide 8: Quality-Centric Operations with Scalable Capabilities
Quality – Centric Operations with Scalable Capabilities Formulation - Ankleshwar, Gujarat API - Navi Mumbai, Maharashtra • Located in the industrial town of Ankleshwar in Gujarat, India; • The API Manufacturing facility consists of three district units, each the Multipurpose plant with dedicated pro
Slide 9: Digital Initiatives: Manufacturing and Quality
Digital Initiatives: Manufacturing and Quality Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Operates Pumps & Scanner enables • Implementation of Utility Asset Chillers according • Safe, reliab
Slide 10: Focusing on execution to drive growth & efficiency
Focusing on execution to drive growth & efficiency Driving improvement across cost, quality, growth & productivity 1 2 3 Strengthening Manufacturing & Driving Cost Efficiency Enhancing Quality & Compliance Capacity Implementing cost optimization Strengthening quality systems and Enhancing capacity a
Slide 11: Business Strategy
Business Strategy 11
Slide 12: Key strategic priorities for our business
Driving a more purpose-led and performance-oriented organization 1 with stronger alignment across teams Scaling core brands with sustained double-digit growth like Naprosyn 2 progressing towards becoming a ₹100 cr+ brand Key strategic Agenda priorities for 3 Building a stronger specialty and chronic
Slide 13: Domestic Formulations (DF) Business: Overview & Strategy
Domestic Formulations (DF) Business: Overview & Strategy Business Overview Leading Textbook Diverse Portfolio Innovation & Growth Specialist Reach Brands Operating across mass, New launches in Strong presence across key Azoran, Aldactone, mass-specialty, and biosimilars, chronic, and specialties (Ca
Slide 14: International Formulations (IF) Business: Overview & Strategy
International Formulations (IF) Business: Overview & Strategy Business Overview Global Reach Specialist Leadership Trusted Partnerships Quality & Expansion Presence in regulated and Strong position in Impeccable supply track Preferred partner for high- emerging markets across immunosuppressants, wit
Slide 15: APIs Business: Overview & Strategy
APIs Business: Overview & Strategy Business Overview Niche API Focus Global Presence Strategic Integration Trusted Partnerships High-value, low-volume Presence across key geographies: Backward integration with Enduring relationships with APIs and mature, stable LATAM, Germany, China, South Internati
Slide 16: Q1 FY27 Performance
Q1- FY27 Performanc 16
Slide 17: Robust Q1 performance with 15.8% revenue growth and 17.0% PAT growth
Robust Q1- 27 performance with 15.8% revenue growth and 17.0% PAT growth 15.8% 17.9% 17.0% Revenue from EBITDA PAT (excl. exceptional items) operations Q1 FY27 v/s Q1 FY26 Q1 FY27 v/s Q1 FY26 Q1 FY27 v/s Q1 FY26 17
Slide 18: Q1 FY27 Financial Performance (Consolidated)
Q1 FY27 Financial Performance (Consolidated) : Revenue up by 15.8% with improved profitability (All values in Rs. Crores) values in circle are margins Revenue from Operations EBITDA & EBITDA Margin +15.8% +17.9% 195.7 48.0 168.9 40.7 24.1% 24.5% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 PBT & PBT Margin PAT &
Slide 19: Q1 FY27: Business Segment-wise Performance Update
Q1 FY27: Business Segment-wise Performance Update All sales value in INR cr. Domestic Formulations contributed 68.3% to total sales in Q1 FY27 +14.8% • Continue to deliver market beating growth 132.5 Domestic • New products contribution improving consistently on account of new launches in 115.4 Form
Slide 20: Long term rating reaffirmed at A+ and outlook retained as stable
RPG Life Sciences ICRA Rating Reaffirmation: A+ rating continues Improvements recorded in ICRA Factors contributing rating Rating- June’26 affirmation • A robust capital structure and strong debt servicing indicators based on: o Healthy cash flows Long term rating reaffirmed o Strong balance sheet o
Slide 21: Key milestones in Q1 FY27
Key milestones in Q1 FY27 RPGLS enters coveted list of “Top Key highlights 50 Pharma Company” in June’26 1 RPGLS has advanced IPM2 ranking from Rank 62 in Mar’25 to Rank 50 in June’26 2 Among the Top 5 Fastest 2 Growing Companies in IPM1 in Q1 FY27 1. Indian pharma market 2. Source: Pharmarack MAT J
Slide 22: Industry awards received in Q1 FY27
Our efforts gaining external recognition; 3 industry awards received in Q1 FY27 Awarded the prestigious “Top Nephrology Company-2026” Awarded for delivering strong patient care through robust portfolio of high-quality medicines in kidney care space Awarded for “Best Use of AI in Sales Force Effectiv
Slide 23: Journey Ahead
Journey Ahead 23
Slide 24: RPGLS Journey Ahead: strategic pillars of action
RPGLS Journey Ahead: 7 strategic pillars of action Portfolio development and • Project underway to grow our immunosuppressant portfolio to 200+ crores 1 mega-brands building • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio • Focus on new geographies, new lau
Slide 25: Thank You
THANK YOU L RPG LIFE SCIENCES